Medicine for shingles

As per available reports about 21 journals, 9 Conferences, 13 workshops are presently dedicated exclusively to medicine for shingles and about 881 articles are being published on the current trends in medicine for shingles. In terms of research annually, USA, India, Japan, Brazil and Canada are some of the leading countries where maximum studies related to medicine for shingles are being carried out. Shingles, also known as herpes zoster, is a distressing skin rash caused by the varicella zoster virus (VZV). This is the same virus that causes chickenpox. After a person has had chickenpox, VZV stays in the body. Usually the virus causes no problems. However, now and again the virus reappears, causing nasty blisters called shingles. There is no cure for shingles, but treatment may shorten the length of illness and prevent complications. Antiviral medicines prevent the virus that causes shingles from multiplying. These medicines shorten the period of rash, reduce pain during the active stage of the illness, and reduce the chance of getting complications of shingles, such as postherpetic neuralgia.

The Journal of Clinical & Experimental Dermatology Research is an academic journal – hosted by OMICS International – a pioneer in open access publishing–and is listed among the top 10 journals in medicine for shingles. Each year research scientists have noticed a rise in the number of congresses being held in this field. The Journal of Clinical & Experimental Dermatology Research provides a unique platform to researchers and scientist to explore the advanced and latest research developments in the field of medicine for shingles thus bridging the gap between researchers and young scientists.

OMICS Group organizing 5th International Conference on Clinical & Experimental Dermatology with the theme “Blooming landscapes in cardio research” with a well reputed organizing committee during July 13-15, 2015 New Orleans, USA.